Project description DEENESFRITPL Novel breast cancer diagnostic test for personalised treatment Breast cancer (BC) is the most common cancer in women worldwide, but current diagnostic tests lack precision, often leading to misdiagnosis and inaccurate treatment. The goal of the EU-funded Multiplex8+ project is the development of a personalised and precise diagnostic test for early and late-stage BC. The test combines two patented multiplexed cancer diagnostic technologies: visualisation (RNA FISH) and RNA sequencing. The combination of these technologies will help to eliminate misdiagnosis and will enable a specific BC barcode system to suggest a particular personalised treatment and estimate its length and prognostic value. The current project stage involves establishing an accredited laboratory for clinical validation followed by the creation of the first high-value biotech company in Slovakia. Show the project objective Hide the project objective Objective Breast cancer (BCa) is the most common cancer in women worldwide with 2.1M new cases diagnosed annually, and this number is expected to double in 2030. However, today’s diagnostic tests lack precision and, as a result, many BCa patients are misdiagnosed then treated inaccurately, putting their lives at risk while creating undue problems for families and healthcare systems. MultiplexDX (a leading Slovak biotechnology company) proposes a personalized and precise diagnostic test for early and late stage BCa called Multiplex8+. The test combines two IP-protected, revolutionary and multiplexed cancer diagnostic technologies, visualization (RNA FISH) and RNA sequencing. By combining the two technologies to eliminate misdiagnosis, Multiplex8+ defines a specific BCa barcode that suggests a specific personalized treatment, length of therapy and clarifies how likely will a BCa patient benefit from chemotherapy or not. There are 2 main objectives of this project: 1. Establish an ISO-15189 accredited laboratory to provide diagnostic services to cancer centers (B2B) and additionally to patients (B2C). A clinical validation on 4 000 tissue samples will be conducted to obtain clinically-based evidence; 2. Build the first successful high-value biotech company in Slovakia. The company has already raised €2,05M in seed investments and grants and started sales of subproducts generating €300k in revenues since 2016. MultiplexDX is operating in the Comenius University Science Park in Bratislava and consists of 17 team members, 5 business and 7 scientific advisors. Our planned accumulated revenues in the first 5 years are €305,3M, generating a net profit of €133,0M and representing a ROI of 10,3. Importantly, Multiplex8+ is supported by the entire oncology value chain (patient associations, cancer centers, hospitals, KOLs, insurance companies, pharma/medtech, clinical laboratories, biobanks, investors, etc.). Fields of science medical and health sciencesclinical medicineoncologybreast cancerengineering and technologymedical engineeringmedical laboratory technologydiagnostic technologiesnatural sciencesbiological sciencesgeneticsRNA Keywords Biotechnology RNA sequencing RNA visualization Breast cancer Cancer diagnostics Cancer profiling Oslo Cancer Cluster Clinical validation Novel cancer biomarkers Health-related biotechnology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-3 Funding Scheme SME-2 - SME instrument phase 2 Coordinator MULTIPLEXDX S.R.O. Net EU contribution € 2 449 527,50 Address Ilkovicova 8 841 04 Bratislava Slovakia See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Slovensko Bratislavský kraj Bratislavský kraj Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 1 049 797,50
